Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

PDS Biotechnology Corporation (PDSB)

8.47   0.05 (0.59%) 11-25 13:00
Open: 8.25 Pre. Close: 8.42
High: 8.64 Low: 8.245
Volume: 234,921 Market Cap: 241(M)

Technical analysis

as of: 2022-11-25 1:59:29 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 11.18     One year: 13.06
Support: Support1: 6.36    Support2: 4.38
Resistance: Resistance1: 9.57    Resistance2: 11.18
Pivot: 7.22
Moving Average: MA(5): 8.49     MA(20): 6.73
MA(100): 4.73     MA(250): 5.4
MACD: MACD(12,26): 1.1     Signal(9): 0.9
Stochastic oscillator: %K(14,3): 78.1     %D(3): 77.6
RSI: RSI(14): 67.9
52-week: High: 9.93  Low: 2.89
Average Vol(K): 3-Month: 745 (K)  10-Days: 3,216 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PDSB ] has closed below upper band by 30.2%. Bollinger Bands are 249.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 8.86 - 8.91 8.91 - 8.95
Low: 8.05 - 8.1 8.1 - 8.15
Close: 8.32 - 8.41 8.41 - 8.49

Company Description

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, human papillomavirus associated malignancies, and cervical cancer. The company is also developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.

Headline News

Thu, 24 Nov 2022
Trustees at Peel District School Board sworn in, chair and vice chair elected - Brampton Guardian

Mon, 21 Nov 2022
2022-11-21 | NDAQ:PDSB | Press Release | PDS Biotechnology Corporation - Stockhouse

Wed, 16 Nov 2022
Is PDS Biotechnology Corp (PDSB) Stock at the Top of the Biotechnology Industry? - InvestorsObserver

Mon, 14 Nov 2022
Healthcare Stocks Moving Up and Down Monday: OPNT, CABA, PDSB, TNYA, SLS, PNT, MOR, STOK - InvestorsObserver

Mon, 14 Nov 2022
PDS Biotechnology (PDSB) Stock Climbs Over 20%: Details - Pulse 2.0

Mon, 14 Nov 2022
PDS Biotechnology Corporation (PDSB) Q3 2022 Earnings Call Transcript - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 28 (M)
Shares Float 26 (M)
% Held by Insiders 14.2 (%)
% Held by Institutions 18.8 (%)
Shares Short 1,400 (K)
Shares Short P.Month 1,300 (K)

Stock Financials

EPS -0.84
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.64
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -24.9
Return on Equity (ttm) -48.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.03
Qtrly Earnings Growth 0
Operating Cash Flow -23 (M)
Levered Free Cash Flow -14 (M)

Stock Valuations

PE Ratio -10.09
PEG Ratio -0.2
Price to Book value 5.13
Price to Sales 0
Price to Cash Flow -10.63

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-03-17
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.